Skip to main content
Top
Published in: Pathology & Oncology Research 2/2012

01-04-2012 | Research

Clinical and Biological Significance of Never in Mitosis Gene A-Related Kinase 6 (NEK6) Expression in Hepatic Cell Cancer

Authors: Xiaolei Cao, Yunfei Xia, Junling Yang, Jinxia Jiang, Li Chen, Runzhou Ni, Liren Li, Zhifeng Gu

Published in: Pathology & Oncology Research | Issue 2/2012

Login to get access

Abstract

Nek6 is a cell cycle regulatory gene, which can control cell proliferation and survival. Recent studies suggested that desregulation of Nek6 expression plays a key role in oncogenesis. This study was aimed to investigate the potential roles of Nek6 in hepatocellular carcinoma (HCC) development. Immunohistochemistry and Western blot analysis was performed for Nek6 in 80 hepatocellular carcinoma samples. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were performed to determine the prognostic significance of Nek6 in HCC. In addition, Nek6 expression vector was used to detect its role in cell cycle control. Nek6 was overexpressed in hepatocellular carcinoma as compared with the adjacent normal tissue. High expression of Nek6 was associated with histological grade and the level of alpha fetal protein, and Nek6 was positively correlated with proliferation marker Ki-67. Univariate analysis showed that Nek6 expression was associated with poor prognosis. Multivariate analysis indicated that Nek6 and Ki-67 protein expression was an independent prognostic marker for HCC. While in vitro, following release from serum starvation of HuH7 HCC cell, the expression of Nek6 was upregulated. Overexpression Nek6 in Huh7 cell could promote the cell cycle. In conclusion, Nek6 is involved in the pathogenesis of hepatocellular carcinoma. It may be a favorable independent poor prognostic parameter for hepatocellular carcinoma.
Literature
2.
go back to reference Di Bisceglie AM (2004) Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127:S104–S107PubMedCrossRef Di Bisceglie AM (2004) Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127:S104–S107PubMedCrossRef
3.
go back to reference Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedCrossRef
4.
go back to reference Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents (IARC, Lyon, France) IARC Scientific Publications, No. 160, Vol. IX Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents (IARC, Lyon, France) IARC Scientific Publications, No. 160, Vol. IX
5.
go back to reference Sean FA, Katherine AM, Marsha ER (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JCO 27(9):1485–1491CrossRef Sean FA, Katherine AM, Marsha ER (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JCO 27(9):1485–1491CrossRef
6.
go back to reference Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S6–S16CrossRef Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S6–S16CrossRef
7.
go back to reference Lai PBS, Tianyi C, George GC (2007) Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 12(2):387–393PubMedCrossRef Lai PBS, Tianyi C, George GC (2007) Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 12(2):387–393PubMedCrossRef
8.
go back to reference Siddhartha K, Meifang W, Brian IC (2008) 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 62(5):831–840CrossRef Siddhartha K, Meifang W, Brian IC (2008) 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 62(5):831–840CrossRef
9.
go back to reference Wang H, Pan K, Zhang H et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(5):535–541PubMedCrossRef Wang H, Pan K, Zhang H et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(5):535–541PubMedCrossRef
10.
go back to reference Laura G, Manuela F, Francesca F et al (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67(13):6092–6099CrossRef Laura G, Manuela F, Francesca F et al (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67(13):6092–6099CrossRef
11.
go back to reference O’Connell MJ, Krien MJ, Hunter T (2003) Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol 13(5):221–228PubMedCrossRef O’Connell MJ, Krien MJ, Hunter T (2003) Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol 13(5):221–228PubMedCrossRef
12.
go back to reference Belham C, Roig J, Caldwell JA et al (2003) A mitotic cascade of NIMA family kinases Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278(37):34897–34909PubMedCrossRef Belham C, Roig J, Caldwell JA et al (2003) A mitotic cascade of NIMA family kinases Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278(37):34897–34909PubMedCrossRef
13.
go back to reference Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934PubMedCrossRef Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934PubMedCrossRef
14.
go back to reference Min Jean Y, Lihua S, David V et al (2003) The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 278(52):52454–52460CrossRef Min Jean Y, Lihua S, David V et al (2003) The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 278(52):52454–52460CrossRef
15.
go back to reference O’Regan L, Fry AM (2009) The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29(14):3975–3990PubMedCrossRef O’Regan L, Fry AM (2009) The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29(14):3975–3990PubMedCrossRef
16.
go back to reference Joseph R, Marta N, Aaron G et al (2008) The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. Journal of Cell Science 121(pt23):3912–3921 Joseph R, Marta N, Aaron G et al (2008) The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. Journal of Cell Science 121(pt23):3912–3921
17.
go back to reference Rounak N, Lihua S, Peter F et al (2010) Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8(5):717–728CrossRef Rounak N, Lihua S, Peter F et al (2010) Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8(5):717–728CrossRef
18.
go back to reference Ahmed S, Thomas G, Ghoussaini M et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2. Nat Genet 41(5):585–590PubMedCrossRef Ahmed S, Thomas G, Ghoussaini M et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2. Nat Genet 41(5):585–590PubMedCrossRef
19.
go back to reference Ke H, John ML, Lee NPY et al (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9:389CrossRef Ke H, John ML, Lee NPY et al (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9:389CrossRef
20.
go back to reference Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef
21.
22.
go back to reference Guillermo C, Ignacio PC, Marcos M (2007) Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14(9):969–985CrossRef Guillermo C, Ignacio PC, Marcos M (2007) Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14(9):969–985CrossRef
23.
go back to reference Marcos M, Mariano B (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60–65CrossRef Marcos M, Mariano B (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60–65CrossRef
24.
go back to reference Chen J, Li L, Zhang Y et al (2006) Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem Biophys Res Commun 341(4):1059–1065PubMedCrossRef Chen J, Li L, Zhang Y et al (2006) Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem Biophys Res Commun 341(4):1059–1065PubMedCrossRef
25.
go back to reference Grigioni WF, D’errico A, Bacci F et al (1989) Primary liver neoplasms: evaluation of proliferative index using MoAb Ki-67. J Pathol 158(1):23–29PubMedCrossRef Grigioni WF, D’errico A, Bacci F et al (1989) Primary liver neoplasms: evaluation of proliferative index using MoAb Ki-67. J Pathol 158(1):23–29PubMedCrossRef
26.
go back to reference Ng IO, Na J, Lai EC et al (1995) Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1: a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 104(3):313–318PubMed Ng IO, Na J, Lai EC et al (1995) Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1: a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 104(3):313–318PubMed
27.
go back to reference Scholzen T, Gerde J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311–322PubMedCrossRef Scholzen T, Gerde J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311–322PubMedCrossRef
28.
go back to reference Pang R, Yuen J, Yuen MF et al (2004) PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23):4182–4186PubMedCrossRef Pang R, Yuen J, Yuen MF et al (2004) PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23):4182–4186PubMedCrossRef
Metadata
Title
Clinical and Biological Significance of Never in Mitosis Gene A-Related Kinase 6 (NEK6) Expression in Hepatic Cell Cancer
Authors
Xiaolei Cao
Yunfei Xia
Junling Yang
Jinxia Jiang
Li Chen
Runzhou Ni
Liren Li
Zhifeng Gu
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9429-0

Other articles of this Issue 2/2012

Pathology & Oncology Research 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine